NYSEAMERICAN:PTNPalatin Technologies Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Palatin Technologies.

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Thursday, September 10th 2020. View our earnings forecast for Palatin Technologies.

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). During the same period last year, the business earned ($0.03) EPS. View Palatin Technologies' earnings history.

2 brokerages have issued 12 month price targets for Palatin Technologies' stock. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 657.9% from the stock's current price. View analysts' price targets for Palatin Technologies.

News articles about PTN stock have trended very negative on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Palatin Technologies earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Palatin Technologies.

Palatin Technologies saw a increase in short interest in June. As of June 30th, there was short interest totaling 21,160,000 shares, an increase of 21.3% from the June 15th total of 17,440,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is currently 10.9 days. Approximately 10.0% of the shares of the company are short sold. View Palatin Technologies' Current Options Chain.

Some companies that are related to Palatin Technologies include Profound Medical (PRN), Renalytix Ai (RENX), Volpara Health Tech (VHT), Legend Biotech (GTH), Akumin (AKU), MaxCyte (MXCT), Exagen (XGN), Yourgene Health (YGEN), Senseonics (SENS), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), SQI Diagnostics (SQD), Genedrive (GDR) and BARD1 Life Sciences (BD1). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), AcelRx Pharmaceuticals (ACRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTN stock can currently be purchased for approximately $0.53.

Palatin Technologies has a market capitalization of $121.00 million. Palatin Technologies employs 19 workers across the globe.

The official website for Palatin Technologies is www.palatin.com.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.